KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Short-term Investments (2017 - 2025)

Emergent BioSolutions (EBS) has 10 years of Short-term Investments data on record, last reported at $3.7 million in Q4 2025.

  • For Q4 2025, Short-term Investments fell 39.34% year-over-year to $3.7 million; the TTM value through Dec 2025 reached $3.7 million, down 39.34%, while the annual FY2025 figure was $3.7 million, 39.34% down from the prior year.
  • Short-term Investments reached $3.7 million in Q4 2025 per EBS's latest filing, roughly flat from $3.7 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $6.5 million in Q3 2024 and bottomed at $100000.0 in Q3 2022.
  • Average Short-term Investments over 4 years is $2.3 million, with a median of $1.3 million recorded in 2024.
  • Peak YoY movement for Short-term Investments: plummeted 50.0% in 2022, then soared 640.0% in 2025.
  • A 4-year view of Short-term Investments shows it stood at $200000.0 in 2021, then tumbled by 50.0% to $100000.0 in 2022, then soared by 6000.0% to $6.1 million in 2024, then plummeted by 39.34% to $3.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Short-term Investments were $3.7 million in Q4 2025, $3.7 million in Q3 2025, and $3.7 million in Q2 2025.